| abstract |
The invention relates to a composition for treating inflammation comprising an amount of an IL-1 and an amount of an IL-18 inhibitor in combination with an amount of a Tumor Necrosis Factor (TNF) inhibitor, wherein the amount of the three components is effective for treating inflammation and a pharmaceutically acceptable carrier. The invention also relates to a combination for treating inflammation comprising, in separate containers, an effective amount of an IL-1 inhibitor, an effective amount of an IL-18 inhibitor and an effective amount of a Tumor Necrosis Factor (TNF) inhibitor for simultaneous, separately or concurrently, administration, or for sequential administration. |